Genedx Holdings CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
GeneDx Holdings Corp. announced a 40% increase in total revenue for fiscal year 2025, driven by exome and genome sequencing, while also disclosing a material weakness in internal control over financial reporting.
NASDAQ
10-K: GeneDx Holdings Corp. Reports Strong Revenue Growth in 2024, Focuses on Exome and Genome Sequencing
GeneDx Holdings Corp. demonstrates significant revenue increase in 2024, driven by exome and genome sequencing, while navigating regulatory changes and strategic realignments.
NASDAQ
GeneDx Holdings Corp.'s 10-K filing provides a detailed description of its registered securities, including common stock, preferred stock, and warrants.